L. Vamvakas

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance

Stella Apostolaki, Maria Perraki, Athanasios Pallis et al. · Annals of Oncology · 2007 · 82 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

John Souglakos, N. Ziras, Stylianos Kakolyris et al. · British Journal of Cancer · 2012 · 64 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

John Souglakos, A. Kalykaki, L. Vamvakas et al. · Annals of Oncology · 2006 · 63 citations

Medicine, Oncology, Pharmacology +13

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

Zenia Saridaki, N. Androulakis, N. Vardakis et al. · British Journal of Cancer · 2012 · 57 citations · Full text

Medicine, Oncology, Pharmacology +10